Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers
Open Access
- 22 February 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Psychiatry
Abstract
Background: Cannabidiol (CBD) is a cannabinoid of potential interest for the treatment of substance use disorders. Our aim was to review the outcome measures, surrogate endpoints, and biomarkers in published and ongoing randomized clinical trials. Methods: We conducted a search in PubMed, Web of Science, PMC, PsycINFO, EMBASE, CENTRAL Cochrane Library, “clinicalTrials.gov,” “clinicaltrialsregister.eu,” and “anzctr.org.au” for published and ongoing studies. Inclusion criteria were randomized clinical trials (RCTs) examining the use of CBD alone or in association with other cannabinoids, in all substance use disorders. The included studies were analyzed in detail and their qualities assessed by a standardized tool (CONSORT 2010). A short description of excluded studies, consisting in controlled short-term or single administration in non-treatment-seeking drug users, is provided. Findings: The screening retrieved 207 published studies, including only 3 RCTs in cannabis use disorder. Furthermore, 12 excluded studies in cannabis, tobacco, and opioid use disorders are described. Interpretation: Primary outcomes were validated withdrawal symptoms scales and drug use reduction in the three RCTs. In the short-term or crossover studies, the outcome measures were visual analog scales for subjective states; self-rated scales for withdrawal, craving, anxiety, or psychotomimetic symptoms; and laboratory tasks of drug-induced craving, effort expenditure, attentional bias for substance, impulsivity, or anxiety to serve as surrogate endpoints for treatment efficacy. Of note, ongoing studies are now adding peripheral biomarkers of the endocannabinoid system status to predict treatment response. Conclusion: The outcome measures and biomarkers assessed in the ongoing CBD trials for substance use disorders are improving.Funding Information
- Ministère des Solidarités et de la Santé (PHRC-national 18-0770)
This publication has 56 references indexed in Scilit:
- Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteersEuropean Journal of Pharmaceutics and Biopharmaceutics, 2020
- Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptorsPharmacological Research, 2020
- Price and product variation in Washington's recreational cannabis marketInternational Journal of Drug Policy, 2019
- Prevalence and correlates of medical cannabis patients' use of cannabis for recreational purposesAddictive Behaviors, 2019
- E-Cigarettes: A Review of New Trends in Cannabis UseInternational Journal of Environmental Research and Public Health, 2015
- Safety and Side Effects of Cannabidiol, a Cannabis sativa ConstituentCurrent Drug Safety, 2011
- Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trialThe Lancet, 2010
- The endocannabinoid system and its therapeutic exploitationNature Reviews Drug Discovery, 2004
- The molecular logic of endocannabinoid signallingNature Reviews Neuroscience, 2003
- Influence of cannabidiol on delta‐9‐tetrahydrocannabinol effectsClinical Pharmacology & Therapeutics, 1976